<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38984497</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-2995</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 antibody levels and long COVID occurrence in blood donors.</ArticleTitle><Pagination><StartPage>1719</StartPage><EndPage>1731</EndPage><MedlinePgn>1719-1731</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/trf.17952</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID is a common condition lacking consensus definition; determinants remain incompletely understood. Characterizing immune profiles associated with long COVID could support the development of preventive and therapeutic strategies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a survey to investigate blood donors' infection/vaccination history and acute/persistent symptoms following COVID-19. The prevalence of long COVID was evaluated using self-report and an adapted definition from the RECOVER study. We evaluated factors associated with long COVID, focusing on anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies. Lastly, we investigated long COVID clinical subphenotypes using hierarchical clustering.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 33,610 participants, 16,003 (48%) reported having had COVID-19; 1853 (12%) had self-reported long COVID, 685 (4%) met an adapted RECOVER definition, and 2050 (13%) met at least one definition. Higher anti-nucleocapsid levels measured 12-24&#x2009;weeks post-infection were associated with higher risk of self-reported and RECOVER long COVID. Higher anti-spike IgG levels measured 12-24&#x2009;weeks post-infection were associated with lower risk of self-reported long COVID. Higher total anti-spike measured 24-48&#x2009;weeks post-infection was associated with lower risk of RECOVER long COVID. Cluster analysis identified four clinical subphenotypes; patterns included neurological and psychiatric for cluster 1; neurological and respiratory for cluster 2; multi-systemic for cluster 3; and neurological for cluster 4.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Long COVID prevalence in blood donors varies depending on the adopted definition. Anti-SARS-CoV-2 antibodies were time-dependently associated with long COVID; higher anti-nucleocapsid levels were associated with higher risk; and higher anti-spike levels were associated with lower risk of long COVID. Different underlying pathophysiologic mechanisms may be associated with distinct clinical subphenotypes.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Transfusion published by Wiley Periodicals LLC on behalf of AABB.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avelino-Silva</LastName><ForeName>Vivian I</ForeName><Initials>VI</Initials><Identifier Source="ORCID">0000-0002-6660-3088</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruhn</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5898-8168</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurita</LastName><ForeName>Karla G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xutao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Elaine A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grebe</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7046-7245</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modeling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Mars</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanteri</LastName><ForeName>Marion C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Creative Testing Solutions, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Bryan R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-9008-9154</Identifier><AffiliationInfo><Affiliation>Scientific Affairs, American Red Cross, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Custer</LastName><ForeName>Brian</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6251-366X</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, California, San Francisco, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>75D30120C08170</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75D30120C08170</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001782" MajorTopicYN="Y">Blood Donors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">COVID&#x2010;19 serological testing</Keyword><Keyword MajorTopicYN="N">blood donors</Keyword><Keyword MajorTopicYN="N">post&#x2010;acute COVID&#x2010;19 syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>10</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38984497</ArticleId><ArticleId IdType="doi">10.1111/trf.17952</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146.</Citation></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection. JAMA. 2023;329(22):1934&#x2013;1946.</Citation></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post&#x2010;acute COVID&#x2010;19 syndrome (PCS) and health&#x2010;related quality of life (HRQoL)&#x2010;a systematic review and meta&#x2010;analysis. J Med Virol. 2022;94(1):253&#x2013;262.</Citation></Reference><Reference><Citation>Cutler DM. The costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809.</Citation></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, Das K, Alekhya G, Venkateshan M, et al. Characteristics and predictors of long COVID among diagnosed cases of COVID&#x2010;19. PLoS One. 2022;17(12):e0278825.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation></Reference><Reference><Citation>Barnkob MB, Potteg&#xe5;rd A, St&#xf8;vring H, Haunstrup TM, Homburg K, Larsen R, et al. Reduced prevalence of SARS&#x2010;CoV&#x2010;2 infection in ABO blood group O. Blood Adv. 2020;4(20):4990&#x2013;4993.</Citation></Reference><Reference><Citation>Al&#x2010;Youha SA, Alduaij W, Al&#x2010;Serri A, Almazeedi SM, Al&#x2010;Haddad M, Jamal MH, et al. The impact of ABO blood groups on clinical outcomes and susceptibility to COVID &#x2010;19: a retrospective study in an unselected population. Transfusion. 2021;61(5):1631&#x2013;1641.</Citation></Reference><Reference><Citation>Abuawwad MT, Taha MJJ, Abu&#x2010;Ismail L, Alrubasy WA, Sameer SK, Abuawwad IT, et al. Effects of ABO blood groups and RH&#x2010;factor on COVID&#x2010;19 transmission, course and outcome: a review. Front Med. 2023;12(9):1045060.</Citation></Reference><Reference><Citation>Moslemi C, S&#xe6;kmose S, Larsen R, Brodersen T, Didriksen M, Hjalgrim H, et al. A large cohort study of the effects of Lewis, ABO, 13 other blood groups, and secretor status on COVID&#x2010;19 susceptibility, severity, and long COVID&#x2010;19. Transfusion. 2023;63(1):47&#x2013;58.</Citation></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. Long&#x2010;term SARS&#x2010;CoV&#x2010;2&#x2010;specific immune and inflammatory responses in individuals recovering from COVID&#x2010;19 with and without post&#x2010;acute symptoms. Cell Rep. 2021;36(6):109518.</Citation></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB. RECOVER mechanistic pathways task force. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;4(12):e86015.</Citation></Reference><Reference><Citation>Jia X, Cao S, Lee AS, Manohar M, Sindher SB, Ahuja N, et al. Anti&#x2010;nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post&#x2013;COVID&#x2010;19 syndrome. JCI Insight. 2022;7(13):e156713.</Citation></Reference><Reference><Citation>Varnai R, Molnar T, Zavori L, T&#x151;k&#xe9;s&#x2010;F&#xfc;zesi M, Illes Z, Kanizsai A, et al. Serum level of anti&#x2010;nucleocapsid, but not anti&#x2010;spike antibody, is associated with improvement of long COVID symptoms. Vaccine. 2022;10(2):165.</Citation></Reference><Reference><Citation>Garc&#xed;a&#x2010;Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez&#x2010;Gonz&#xe1;lez M, Garc&#xed;a JA, Agull&#xf3; V, Andreo M, et al. Antibody response to SARS&#x2010;CoV&#x2010;2 is associated with Long&#x2010;term clinical outcome in patients with COVID&#x2010;19: a longitudinal study. J Clin Immunol. 2021;41(7):1490&#x2013;1501.</Citation></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post&#x2010;COVID syndrome in non&#x2010;hospitalised patients with COVID&#x2010;19: a longitudinal prospective cohort study. Lancet Region Health. 2021;6:100122.</Citation></Reference><Reference><Citation>Hsu FC, Pan LC, Huang YF, Yang CH, Shiu MN, Lin HJ. A dynamic model for estimating the retention duration of neutralizing antibody titers after vaccination in a COVID&#x2010;19 convalescent population. J Infect Dis. 2024;229(2):398&#x2013;402. https://doi.org/10.1093/infdis/jiad431</Citation></Reference><Reference><Citation>Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS&#x2010;CoV&#x2010;2 infection in humans. Nat Microbiol. 2020;5(12):1598&#x2013;1607.</Citation></Reference><Reference><Citation>Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021;223(3):389&#x2013;398.</Citation></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, et al. Data&#x2010;driven identification of post&#x2010;acute SARS&#x2010;CoV&#x2010;2 infection subphenotypes. Nat Med. 2023;29(1):226&#x2013;235.</Citation></Reference><Reference><Citation>Kenny G, McCann K, O'Brien C, Savinelli S, Tinago W, Yousif O, et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self&#x2010;reported symptoms. Open Forum Infect Dis. 2022;9(4):ofac060.</Citation></Reference><Reference><Citation>Gentilotti E, G&#xf3;rska A, Tami A, Gusinow R, Mirandola M, Rodr&#xed;guez Ba&#xf1;o J, et al. Clinical phenotypes and quality of life to define post&#x2010;COVID&#x2010;19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. eClinicalMedicine. 2023;62:102107.</Citation></Reference><Reference><Citation>Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, et al. Large&#x2010;scale phenotyping of patients with long COVID post&#x2010;hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024;25(4):607&#x2013;621.</Citation></Reference><Reference><Citation>Busch MP, Stramer SL, Stone M, Yu EA, Grebe E, Notari E, et al. Population&#x2010;weighted seroprevalence from severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) infection, vaccination, and hybrid immunity among US blood donations from January to December 2021. Clinic Infect Dis. 2022;75(Supplement_2):S254&#x2013;S263.</Citation></Reference><Reference><Citation>Jones JM, Opsomer JD, Stone M, Benoit T, Ferg RA, Stramer SL, et al. Updated US infection&#x2010; and vaccine&#x2010;induced SARS&#x2010;CoV&#x2010;2 seroprevalence estimates based on blood donations, July 2020&#x2010;December 2021. JAMA. 2022;328(3):298&#x2013;301.</Citation></Reference><Reference><Citation>Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US infection&#x2010; and vaccine&#x2010;induced SARS&#x2010;CoV&#x2010;2 seroprevalence based on blood donations, July 2020&#x2010;May 2021. JAMA. 2021;326(14):1400&#x2013;1409.</Citation></Reference><Reference><Citation>Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572&#x2013;1573.</Citation></Reference><Reference><Citation>Shah MM, Spencer BR, James&#x2010;Gist J, Haynes JM, Feldstein LR, Stramer SL, et al. Long&#x2010;term symptoms associated with SARS&#x2010;CoV&#x2010;2 infection among blood donors. JAMA Netw Open. 2024;7(4):e245611.</Citation></Reference><Reference><Citation>Cabrera Martimbianco AL, Pacheco RL, Bagattini &#xc2;M, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID&#x2010;19: a systematic review. Int J Clin Pract. 2021;75(10):e14357.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or Post&#x2010;COVID conditions. [Internet]. [cited 2023 Dec 14]. Available from: https://www.cdc.gov/coronavirus/2019&#x2010;ncov/long&#x2010;term&#x2010;effects/index.html#:~:text=Long%20COVID%20is%20broadly%20defined,after%20acute%20COVID%2D19%20infection</Citation></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139&#x2013;148.</Citation></Reference><Reference><Citation>Files JK, Sarkar S, Fram TR, Boppana S, Sterrett S, Qin K, et al. Duration of post&#x2010;COVID&#x2010;19 symptoms are associated with sustained SARS&#x2010;CoV&#x2010;2 specific immune responses. JCI Insight [Internet]. 2021 Jun 18 [cited 2023 Dec 14]; Available from: http://insight.jci.org/articles/view/151544</Citation></Reference><Reference><Citation>Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, et al. Persistent symptoms after COVID&#x2010;19 are not associated with differential SARS&#x2010;CoV&#x2010;2 antibody or T cell immunity. Nat Commun. 2023;14(1):5139.</Citation></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID&#x2010;19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2013;1198.</Citation></Reference><Reference><Citation>Pereira C, Harris BHL, Di Giovannantonio M, Rosadas C, Short CE, Quinlan R, et al. The association between antibody response to severe acute respiratory syndrome coronavirus 2 infection and Post&#x2010;COVID&#x2010;19 syndrome in healthcare workers. J Infect Dis. 2021;223(10):1671&#x2013;1676.</Citation></Reference><Reference><Citation>Imai K, Kitagawa Y, Tabata S, Kubota K, Nagura&#x2010;Ikeda M, Matsuoka M, et al. Antibody response patterns in COVID&#x2010;19 patients with different levels of disease severity in Japan. J Med Virol. 2021;93(5):3211&#x2013;3218.</Citation></Reference><Reference><Citation>Yan X, Chen G, Jin Z, Zhang Z, Zhang B, He J, et al. Anti&#x2010;SARS&#x2010;CoV&#x2010;2 IgG levels in relation to disease severity of COVID&#x2010;19. J Med Virol. 2022;94(1):380&#x2013;383.</Citation></Reference><Reference><Citation>Kallaste A, Kisand K, Aart A, Kisand K, Peterson P, Lember M. Antibody levels remain high to one&#x2010;year's follow&#x2010;up after moderate and severe COVID&#x2010;19, but not after mild cases. Infect Dis. 2022;54(5):345&#x2013;355.</Citation></Reference><Reference><Citation>Pl&#x16b;me J, Galvanovskis A, &#x160;mite S, Romanchikova N, Zayakin P, Lin&#x113; A. Early and strong antibody responses to SARS&#x2010;CoV&#x2010;2 predict disease severity in COVID&#x2010;19 patients. J Transl Med. 2022;20(1):176.</Citation></Reference><Reference><Citation>Bl&#xe4;ckberg A, Fernstr&#xf6;m N, Sarbrant E, Rasmussen M, Sunnerhagen T. Antibody kinetics and clinical course of COVID&#x2010;19 a prospective observational study. PLoS One. 2021;16(3):e0248918.</Citation></Reference><Reference><Citation>Stich M, Benning L, Speer C, Garbade SF, Bartenschlager M, Kim H, et al. Waning immunity 14 months after SARS&#x2010;CoV&#x2010;2 infection. Pediatrics. 2022;150(5):e2022057151.</Citation></Reference><Reference><Citation>Ishizaki A, Bi X, Nguyen QT, Maeno T, Hara A, Nakamura H, et al. Neutralizing&#x2010;antibody response to SARS&#x2010;CoV&#x2010;2 for 12 months after the COVID&#x2010;19 workplace outbreaks in Japan. PLoS One. 2022;17(8):e0273712.</Citation></Reference><Reference><Citation>Montesinos I, Dahma H, Wolff F, Dauby N, Delaunoy S, Wuyts M, et al. Neutralizing antibody responses following natural SARS&#x2010;CoV&#x2010;2 infection: dynamics and correlation with commercial serologic tests. J Clin Virol. 2021;144:104988.</Citation></Reference><Reference><Citation>Garcia&#x2010;Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID&#x2010;19&#x2010;neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476&#x2013;488.e11.</Citation></Reference><Reference><Citation>Tsuchida T, Yoshimura N, Ishizuka K, Katayama K, Inoue Y, Hirose M, et al. Five cluster classifications of long COVID and their background factors: a cross&#x2010;sectional study in Japan. Clin Exp Med. 2023;23(7):3663&#x2013;3670.</Citation></Reference><Reference><Citation>Fischer A, Badier N, Zhang L, Elb&#xe9;ji A, Wilmes P, Oustric P, et al. Long COVID classification: findings from a clustering analysis in the Predi&#x2010;COVID cohort study. Int J Environ Res Public Health. 2022;19(23):16018.</Citation></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413.</Citation></Reference><Reference><Citation>Fink RV, Fisher L, Sulaeman H, Dave H, Levy ME, McCann L, et al. How do we &#x2026;form and coordinate a national serosurvey of SARS&#x2010;CoV&#x2010;2 within the blood collection industry? Transfusion. 2022;62(7):1321&#x2013;1333.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>